Hymenoptera venom allergy in children and adolescents.

IF 3 4区医学 Q2 ALLERGY Current Opinion in Allergy and Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI:10.1097/ACI.0000000000001013

Francesca Norelli, Valentina Gueli, Patrizia Bonadonna

{"title":"Hymenoptera venom allergy in children and adolescents.","authors":"Francesca Norelli, Valentina Gueli, Patrizia Bonadonna","doi":"10.1097/ACI.0000000000001013","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review will identify and summarize the published existing data pertaining specifically to Hymenoptera venom allergy in children and adolescents, highlighting the major studies currently available on venom immunotherapy (VIT) and its prognosis in children.Recent findings: The current review covers the incidence and prevalence of Hymenoptera venom allergy (HVA) in children, factors influencing occurrence and severity of reactions (age, sex, comorbidities, etc.), indications to perform diagnostic tests and start VIT in children, different existing VIT protocols and their safety and efficacy.Summary: Hymenoptera venom allergy is the second most common cause of anaphylaxis in children and it considerably affects quality of life. Cutaneous reactions are the most prevalent clinical presentation in children who usually have a more favourable prognosis than adult patients. However, studies on HVA in children and adolescents are still limited. Currently VIT is the only treatment able to modify the natural history of HVA in adults as well as in children, and to protect patients from systemic reactions after subsequent stings.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"322-329"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ACI.0000000000001013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review will identify and summarize the published existing data pertaining specifically to Hymenoptera venom allergy in children and adolescents, highlighting the major studies currently available on venom immunotherapy (VIT) and its prognosis in children.

Recent findings: The current review covers the incidence and prevalence of Hymenoptera venom allergy (HVA) in children, factors influencing occurrence and severity of reactions (age, sex, comorbidities, etc.), indications to perform diagnostic tests and start VIT in children, different existing VIT protocols and their safety and efficacy.

Summary: Hymenoptera venom allergy is the second most common cause of anaphylaxis in children and it considerably affects quality of life. Cutaneous reactions are the most prevalent clinical presentation in children who usually have a more favourable prognosis than adult patients. However, studies on HVA in children and adolescents are still limited. Currently VIT is the only treatment able to modify the natural history of HVA in adults as well as in children, and to protect patients from systemic reactions after subsequent stings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

儿童和青少年对膜翅目昆虫毒液过敏。

综述的目的：本综述将确定并总结已发表的与儿童和青少年膜翅目昆虫毒液过敏有关的现有数据，重点介绍目前有关毒液免疫疗法（VIT）及其在儿童中的预后的主要研究：目前的综述涵盖了儿童膜翅目毒液过敏（HVA）的发病率和流行率、影响反应发生和严重程度的因素（年龄、性别、合并症等）、对儿童进行诊断测试和开始 VIT 的适应症、现有的不同 VIT 方案及其安全性和有效性。摘要：膜翅目毒液过敏是儿童过敏性休克的第二大常见原因，严重影响生活质量。皮肤反应是儿童最常见的临床表现，与成年患者相比，他们的预后通常较好。然而，有关儿童和青少年 HVA 的研究仍然有限。目前，VIT 是唯一一种能够改变成人和儿童 HVA 自然病史的治疗方法，并能保护患者在随后的蛰伤后免受全身反应的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Allergy and Clinical Immunology 医学-过敏

CiteScore

5.90

自引率

3.60%

发文量

109

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on one to three topics, every issue of Current Opinion in Allergy and Clinical Immunology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as upper airway disease; mechanisms of allergy and adult asthma; paediatric asthma and development of atopy; food and drug allergies; and immunotherapy.

期刊最新文献

Real-world evidence of allergen immunotherapy. eHealth in pediatric respiratory allergy. Allergen-specific immunotherapy at the extremes of age: below 5 years and elderly: evidence beyond indications? Liver disease in primary antibody deficiencies. Cost-effectiveness of allergen immunotherapy.